Roland Njoh, MD
Cardiovascular Disease · Poplar Bluff, MONPI 1932429719
Payments from drug & device makers
Across 338 payments — averaging $60.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardiovascular Systems Inc.$6K
- Boston Scientific$4K
- Abbott$4K
- Angiodynamics, Inc.$2K
- Medtronic$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$551
- plus $3K from 22 others
What the payments were for
- Speaking & faculty fees$3,50017%
- Travel & lodging$8,29341%
- Food & beverage$8,38541%
- Education$2051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cardiovascular Systems Inc. | 35 | $6,440 |
| Boston Scientific | 69 | $3,900 |
| Abbott | 76 | $3,574 |
| Angiodynamics, Inc. | 26 | $2,236 |
| Medtronic | 11 | $1,136 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $551 |
| Abiomed | 8 | $396 |
| Shockwave Medical, Inc | 7 | $326 |
| Philips North America LLC | 5 | $285 |
| Amgen | 19 | $282 |
| Inari Medical, Inc. | 4 | $269 |
| Bard Peripheral Vascular, Inc. | 14 | $208 |
| E.r. Squibb & Sons, L.L.C. | 7 | $95 |
| ZOLL Circulation Inc | 3 | $90 |
| Penumbra, Inc. | 2 | $77 |
| Pfizer | 5 | $67 |
| Stryker | 3 | $66 |
| AstraZeneca | 5 | $61 |
| Merck | 4 | $57 |
| Johnson & Johnson | 4 | $54 |
| BD | 1 | $48 |
| W. L. Gore & Associates, Inc. | 1 | $41 |
| Cordis US CORP. | 1 | $28 |
| Lantheus Medical Imaging, Inc. | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 2 | $25 |
| Novartis | 1 | $15 |
| Elutia, Inc. | 1 | $14 |
| Elite Orthopedics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Diamondback Peripheral$3,643
- VersaCross Access Solution$2,325
- Peripheral Orbital Atherectomy System$2,271
- AVEIR$1,382
- Micra$865
- Diamondback Coronary$310
- Auryon Laser System 100-120 Vac$243
- VenaCure 1470 Pro$193
- XIENCE SKYPOINT$155
- IGT Devices Und$155
- Supera peripheral stent system$147
- FLOWTRIEVER CATHETER, S$145
- CT THROMBECTOMY SYSTEM KIT$145
- AVVIGO Guidance System$133
- Impella$100
How this compares
$20,383 in reported general payments places this provider in the 80th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 399 | $374,771 |
| BrilintaTicagrelor | 157 | $97,911 |
| EntrestoSacubitril/Valsartan | 62 | $85,769 |
| XareltoRivaroxaban | 93 | $77,988 |
| Repatha SureclickEvolocumab | 31 | $27,368 |
| FarxigaDapagliflozin Propanediol | 23 | $24,732 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $13,734 |
| Midodrine Hcl | 53 | $6,986 |
| Bumetanide | 107 | $6,913 |
| Flecainide Acetate | 109 | $6,570 |
| Ranolazine ErRanolazine | 60 | $6,140 |
| Potassium Chloride | 380 | $5,862 |
| ClopidogrelClopidogrel Bisulfate | 502 | $3,965 |
| Metoprolol Succinate | 476 | $3,775 |
| Valsartan | 165 | $3,334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $67 | $374,771399 claims |
| AstraZenecaBrilinta, Farxiga | $61 | $122,644180 claims |
| NovartisEntresto | $15 | $85,76962 claims |
| Johnson & JohnsonXarelto | $54 | $77,98893 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Poplar Bluff
- Mikhail KosiborodKansas City$27.8M
- Mohammad TahirSaint Louis$2.7M
- John SpertusKansas City$2.3M
- Joshua MitchellSaint Louis$1.4M
- Nathan StitzielSaint Louis$1.2M
- Daniel KellySaint Louis$1.1M
- Georges ChahoudSaint Louis$967K
- Jiafu OuSaint Louis$853K
- William BowenSaint Louis$726K
- Omar AlmousalliFestus$690K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.